The HER3 inhibitors Market is gaining significant traction as a promising area within cancer therapeutics, driven by breakthroughs in tumor biology, smarter patient selection tools, and a focused effort to tackle drug resistance. HER3 (ErbB3), once dismissed as a weak player in the ErbB receptor family, is now recognized as a key driver of resistance to HER2 and EGFR therapies and a major...